Health Care

4516 posts

Control Bionics obtains FDA registration and device listing for NeuroStrip

Control Bionics' NeuroStrip platform has been registered and listed with the US Food and Drug Administration…
Aussie cash

Struggling long-term Lumos holders see hope as biotech stock inks A$1.1M order

The thing about biotech is that when a stock gets key approvals and smashes its third-phase-trial goals, it can tend to make overnight

Noxopharm adds to cancer treatment pipeline with positive new study results

Noxopharm’s new preclinical data has demonstrated the potential of its cancer-fighting technology and immune-amplifying oligonucleotides.

Wide Open Agriculture confirms multi-billion dollar skin care potential of lupin oil product

Wide Open Agriculture’s lupin oil product has been confirmed for both safety and its skin hydration…

Paradigm completes Phase 3 enrolment as Zilosul trial moves toward interim analysis

Paradigm Biopharmaceuticals has completed enrolment in its Phase 3 knee osteoarthritis trial, with top-line results expected…

AFT Pharmaceuticals identifies multi-billion-dollar market potential with expanding portfolio

AFT Pharmaceuticals has unveiled new growth opportunities in its research and development portfolio and within its…

Hydrix secures A$3.4M US medical robotics contract with Remedy Robotics

Hydrix has secured a $3.4M contract with Remedy Robotics to support its next-generation N1 robotic platform…

Pacific Edge’s APAC operations advancing towards profit with cancer test growth

Pacific Edge APAC business is advancing towards profitability on a direct-cost basis with a growing interest…
Diabetes concept

Entropy reports 50% remission in Phase 2 psychedelic trial for binge eating disorder

Entropy Neurodynamics says its Phase 2 trial of TRP-8803 delivered 50% remission in all treatment-resistant binge…
The Market Online Video

Syntara shows encouraging first signals it can impact the path to Parkinson’s

Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence